Company Profiles

driven by the PitchBook Platform

ADC Therapeutics

Description

Developer of antibody drug conjugate (ADC) products. The company is developing proprietary antibody and non-antibody drug conjugate products that target hematological cancers and tumor cells. It specializes in the development of targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads.

2012

Founded

PRIVATE

Status

11-50

Employees

Early Stage VC

Latest Deal Type

$105M

Latest Deal Amount

$275M

Total Amount Raised

Description

Developer of antibody drug conjugate (ADC) products. The company is developing proprietary antibody and non-antibody drug conjugate products that target hematological cancers and tumor cells. It specializes in the development of targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads.

Website:

www.adctherapeutics.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Pharmaceuticals
Drug Delivery

Primary Office

Route de la Corniche 3B 1066 EpalingesSwitzerland +41 (0)21 653 0200
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore ADC Therapeutics's full profile, request a free trial.

ADC Therapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

ADC Therapeutics Investors (6)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
AstraZenecaCorporationMinority000 0000000 0000
Auven TherapeuticsPE/BuyoutMinority000 0000000 0000
Cancer Research TechnologyVenture CapitalMinority000 0000000 0000
ET CapitalVenture CapitalMinority000 0000000 0000
MedImmune VenturesCorporate Venture CapitalMinority000 0000000 0000
AstraZeneca Corporation
Auven Therapeutics PE/Buyout
Cancer Research Technology Venture Capital
ET Capital Venture Capital
MedImmune Ventures Corporate Venture Capital

ADC Therapeutics Executive Team (13)

NameTitleBoard
Seat
Contact
Info
Chris Martin Ph.DChief Executive Officer & Board Member
Michael ForerVice Chairman, Executive Vice President & Chief Financial Officer
Stuart BarlowChief Accounting Officer & Group Treasurer
Stephane HenchozDirector, Finance
Maria CincottaExecutive Director of Clinical Operations
Chris Martin Ph.D Chief Executive Officer & Board Member
Michael Forer Vice Chairman, Executive Vice President & Chief Financial Officer
Stuart Barlow Chief Accounting Officer & Group Treasurer
Stephane Henchoz Director, Finance
Maria Cincotta Executive Director of Clinical Operations

ADC Therapeutics Board Members (9)

NameRepresentingRoleSinceContact
Info
Bahija Jallal Ph.DMedImmuneHead000 0000
Barrie Ward Ph.DSelfBoard Member000 0000
Chris Martin Ph.DADC TherapeuticsChief Executive Officer & Board Member000 0000
Hans-Peter WildSelfBoard Member000 0000
Jacques TheurillatSelfBoard Member000 0000
Bahija Jallal Ph.D Head MedImmune
Barrie Ward Ph.D Board Member Self
Chris Martin Ph.D Chief Executive Officer & Board Member ADC Therapeutics
Hans-Peter Wild Board Member Self
Jacques Theurillat Board Member Self
Request full access to PitchBook